Matches in SemOpenAlex for { <https://semopenalex.org/work/W2991916389> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2991916389 endingPage "4411" @default.
- W2991916389 startingPage "4411" @default.
- W2991916389 abstract "Abstract Objective: To assess the long term survival of patients with refractory leukemia treated by HLA haploidentical stem cell transplantation. Methods To analysis the outcomes of 48 cases patients with refractory leukemia underwent HLA haploidentical stem cell transplantations from August, 1998 to May, 2008. The median age was 16 years old (7–52 years old). Patients received stem cells from their parants, daughter, son, and sibling donors. Twelve patients received three HLA locus mismatched stem cells and twenty patients received two HLA locus mismatched donors stem cells. Sixteen patients were grafted one HLA mismatched donors stem cells. The conditioning regime consisted of fludara (25mg/m2 × 5d), busulfan (4mg/kg × 4d) and cyclophosphamide (60mg/kg × 2d). Median dose of rabbit anti-human lymphocyte globulin (5mg/kg × 5d) was added. CSA combined with short course of MTX were used for prophylaxis GVHD. A median dose of 6.0 × 108/kg(3–9 ×108/kg) mono-nucleated cells was grafted. The mean CD34+ cells number was 5.5 × 106/kg (3–6.5 × 106/kg) Results Forty-seven patients were successfully to be engraftment and one failed to be engraftment. The median time of white cells and platelet reconstitution was 14 days (11–20 days) and 18 days (14–20) respectively. Severe acute graft versus host disease occurred in seven patients, and six died. Seven patients suffered from intensive chronic graft versus host disease and four died with fungus infection. Seven patients relapsed and died. The median relapse time was 6 months (3 months to 24 months). Three patients died from severe diarrhea with CMV infection. Four patients died from intensive chronic graft versus host disease. Twenty patients are still survival and disease free with high karnofsky performance scores. The disease free survival is 45 percent as follow up 3 years (1 to 7 years). Conclusion: HLA haploidentical peripheral blood stem cell transplantation may be an effect therapy to refractory leukemia. And some refractory leukemia patients could benefit from HLA haploidentical peripheral blood stem cell transplantation." @default.
- W2991916389 created "2019-12-13" @default.
- W2991916389 creator A5000524663 @default.
- W2991916389 creator A5068220116 @default.
- W2991916389 creator A5074012582 @default.
- W2991916389 date "2008-11-16" @default.
- W2991916389 modified "2023-10-16" @default.
- W2991916389 title "Long Term Survival in Refractory Leukemia Patient Treated with Related HLA Haploidentical Stem Cell Transplantation" @default.
- W2991916389 doi "https://doi.org/10.1182/blood.v112.11.4411.4411" @default.
- W2991916389 hasPublicationYear "2008" @default.
- W2991916389 type Work @default.
- W2991916389 sameAs 2991916389 @default.
- W2991916389 citedByCount "4" @default.
- W2991916389 countsByYear W29919163892013 @default.
- W2991916389 countsByYear W29919163892017 @default.
- W2991916389 countsByYear W29919163892023 @default.
- W2991916389 crossrefType "journal-article" @default.
- W2991916389 hasAuthorship W2991916389A5000524663 @default.
- W2991916389 hasAuthorship W2991916389A5068220116 @default.
- W2991916389 hasAuthorship W2991916389A5074012582 @default.
- W2991916389 hasConcept C126322002 @default.
- W2991916389 hasConcept C141071460 @default.
- W2991916389 hasConcept C2776694085 @default.
- W2991916389 hasConcept C2776755627 @default.
- W2991916389 hasConcept C2777408962 @default.
- W2991916389 hasConcept C2778461978 @default.
- W2991916389 hasConcept C2779972918 @default.
- W2991916389 hasConcept C2780611847 @default.
- W2991916389 hasConcept C28328180 @default.
- W2991916389 hasConcept C2911091166 @default.
- W2991916389 hasConcept C54355233 @default.
- W2991916389 hasConcept C71924100 @default.
- W2991916389 hasConcept C86803240 @default.
- W2991916389 hasConcept C90924648 @default.
- W2991916389 hasConceptScore W2991916389C126322002 @default.
- W2991916389 hasConceptScore W2991916389C141071460 @default.
- W2991916389 hasConceptScore W2991916389C2776694085 @default.
- W2991916389 hasConceptScore W2991916389C2776755627 @default.
- W2991916389 hasConceptScore W2991916389C2777408962 @default.
- W2991916389 hasConceptScore W2991916389C2778461978 @default.
- W2991916389 hasConceptScore W2991916389C2779972918 @default.
- W2991916389 hasConceptScore W2991916389C2780611847 @default.
- W2991916389 hasConceptScore W2991916389C28328180 @default.
- W2991916389 hasConceptScore W2991916389C2911091166 @default.
- W2991916389 hasConceptScore W2991916389C54355233 @default.
- W2991916389 hasConceptScore W2991916389C71924100 @default.
- W2991916389 hasConceptScore W2991916389C86803240 @default.
- W2991916389 hasConceptScore W2991916389C90924648 @default.
- W2991916389 hasIssue "11" @default.
- W2991916389 hasLocation W29919163891 @default.
- W2991916389 hasOpenAccess W2991916389 @default.
- W2991916389 hasPrimaryLocation W29919163891 @default.
- W2991916389 hasRelatedWork W2023136491 @default.
- W2991916389 hasRelatedWork W2072244040 @default.
- W2991916389 hasRelatedWork W2366793411 @default.
- W2991916389 hasRelatedWork W2383304976 @default.
- W2991916389 hasRelatedWork W2390476964 @default.
- W2991916389 hasRelatedWork W2559999242 @default.
- W2991916389 hasRelatedWork W2560664961 @default.
- W2991916389 hasRelatedWork W2979354104 @default.
- W2991916389 hasRelatedWork W3118922640 @default.
- W2991916389 hasRelatedWork W3212134050 @default.
- W2991916389 hasVolume "112" @default.
- W2991916389 isParatext "false" @default.
- W2991916389 isRetracted "false" @default.
- W2991916389 magId "2991916389" @default.
- W2991916389 workType "article" @default.